A detailed history of Advisors Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 19,853 shares of EXEL stock, worth $660,906. This represents 0.01% of its overall portfolio holdings.

Number of Shares
19,853
Previous 19,244 3.16%
Holding current value
$660,906
Previous $432,000 19.21%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$21.96 - $27.6 $13,373 - $16,808
609 Added 3.16%
19,853 $515,000
Q2 2024

Aug 14, 2024

SELL
$20.34 - $23.73 $36,001 - $42,002
-1,770 Reduced 8.42%
19,244 $432,000
Q1 2024

May 14, 2024

BUY
$20.17 - $23.93 $111,197 - $131,926
5,513 Added 35.57%
21,014 $498,000
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $37,056 - $46,450
1,925 Added 14.18%
15,501 $371,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $50,603 - $57,036
-2,785 Reduced 17.02%
13,576 $259,000
Q1 2023

May 12, 2023

SELL
$16.3 - $19.41 $16,984 - $20,225
-1,042 Reduced 5.99%
16,361 $317,000
Q4 2022

Feb 13, 2023

SELL
$14.96 - $17.39 $174,089 - $202,367
-11,637 Reduced 40.07%
17,403 $279,000
Q3 2022

Nov 08, 2022

SELL
$15.68 - $22.27 $62,688 - $89,035
-3,998 Reduced 12.1%
29,040 $455,000
Q2 2022

Aug 08, 2022

SELL
$17.44 - $23.16 $228,900 - $303,975
-13,125 Reduced 28.43%
33,038 $688,000
Q1 2022

May 17, 2022

SELL
$17.03 - $22.67 $224,659 - $299,062
-13,192 Reduced 22.23%
46,163 $1.05 Million
Q4 2021

Feb 15, 2022

BUY
$15.84 - $21.88 $42,118 - $58,178
2,659 Added 4.69%
59,355 $1.09 Million
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $41,190 - $53,420
2,527 Added 4.67%
56,696 $1.2 Million
Q2 2021

Jul 30, 2021

BUY
$17.95 - $25.56 $269,196 - $383,323
14,997 Added 38.28%
54,169 $987,000
Q1 2021

May 07, 2021

BUY
$20.53 - $25.22 $331,744 - $407,529
16,159 Added 70.22%
39,172 $885,000
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $292,014 - $393,799
15,879 Added 222.58%
23,013 $462,000
Q3 2020

Nov 16, 2020

BUY
$20.67 - $26.94 $68,314 - $89,036
3,305 Added 86.31%
7,134 $174,000
Q2 2020

Aug 12, 2020

BUY
$16.46 - $27.42 $63,025 - $104,991
3,829 New
3,829 $91,000
Q3 2019

Nov 14, 2019

SELL
$17.68 - $22.65 $68,510 - $87,768
-3,875 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $51,584 - $67,443
-2,725 Reduced 41.29%
3,875 $83,000
Q1 2019

May 15, 2019

SELL
$19.6 - $24.76 $51,548 - $65,118
-2,630 Reduced 28.49%
6,600 $157,000
Q4 2018

Jan 31, 2019

SELL
$13.65 - $21.8 $11,411 - $18,224
-836 Reduced 8.31%
9,230 $182,000
Q3 2018

Nov 15, 2018

BUY
$15.87 - $22.4 $2,920 - $4,121
184 Added 1.86%
10,066 $178,000
Q2 2018

Aug 22, 2018

SELL
$18.56 - $22.45 $580,668 - $702,370
-31,286 Reduced 76.0%
9,882 $213,000
Q2 2018

Aug 15, 2018

BUY
$18.56 - $22.45 $371,664 - $449,561
20,025 Added 94.71%
41,168 $213,000
Q1 2018

May 15, 2018

BUY
$22.15 - $31.89 $57,412 - $82,658
2,592 Added 13.97%
21,143 $545,000
Q4 2017

Feb 13, 2018

BUY
$24.23 - $30.93 $56,383 - $71,974
2,327 Added 14.34%
18,551 $564,000
Q3 2017

Nov 07, 2017

BUY
$23.35 - $29.24 $378,830 - $474,389
16,224
16,224 $393,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.